Lymphoma

On April 1, 2022, Kite, a subsidiary of Gilead Sciences, announced that the U.S. Food and Drug Administration (FDA) has approved their CAR-T cell therapy product Yescarta® for the treatment of adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or relapses within 12 months after first-line chemoimmunotherapy.

On October 17, 2022, exciting news came from the European Commission (EC). Based on the data from the ZUMA-7 study, the EC officially approved a new indication for Yescarta® for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL) after one line of chemoimmunotherapy failed or within 12 months of first-line chemoimmunotherapy.

On December 17, 2020, Gilead’s subsidiary Kite’s CD19 CAR-T cell therapy Tecartus (KTE-X19) received conditional marketing authorization in the European Union for the treatment of relapsed or refractory mantle cell lymphoma (r/r MCL).

This article delves into the specifics of Kymriah’s EMA approval, its mechanisms, clinical trial data, and its impact on patient care.

On May 1, 2018, the U.S. Food and Drug Administration (FDA) approved Novartis’ Tisagenlecleucel (Kymriah) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (FL).

Chimeric antigen receptor T (CAR-T) cell therapy has shown promising efficacy in early trials for relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Priced at $373,000, understanding the cost implications, benefits, and overall impact of Yescarta is crucial for patients and healthcare providers alike.

At the recent 2024 European Hematology Association (EHA) Annual Meeting, the research achievements of Professor Pan Jing’s team from Beijing Gaobeidian Hospital attracted widespread attention.

Kymriah (Tisagenlecleucel) is a CAR-T cell immunotherapy co-developed by the University of Pennsylvania and Novartis, a revolutionary immunocellular therapy.

Serum Eotaxin Predicts Long-Term Survival of Patients with Relapsed/Refractory Aggressive B-Cell Lymphoma Receiving CD19 CAR-T Therapy.

CAR-T cell therapy is an innovative treatment for cancer. The million-dollar CAR-T cell injection has saved the lives of countless patients with difficult-to-treat, relapsed lymphomas, including diffuse large B-cell lymphoma (DLBCL).

Axicabtagene Ciloleucel (axi-cel) Can Provide Durable Remission for Patients with R/R Primary Mediastinal B-Cell Lymphoma (PMBCL).